Resistance to targeted therapy in leukaemia

被引：14

作者：

Griffin, JD ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Leukemia Program, Boston, MA 02115 USA

来源：

LANCET | 2002年 / 359卷 / 9305期

关键词：

D O I：

10.1016/S0140-6736(02)07671-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：458 / 459

页数：2

共 7 条

[1] All trans retinoic acid in acute promyelocytic leukemia [J].

Degos, L ;

Wang, ZY .

ONCOGENE, 2001, 20 (49) :7140-7145

[2] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[3] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[4] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[5]

Merx K, 2001, BLOOD, V98, p846A

[6] Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase [J].

Schindler, T ;

Bornmann, W ;

Pellicena, P ;

Miller, WT ;

Clarkson, B ;

Kuriyan, J .

SCIENCE, 2000, 289 (5486) :1938-1942

[7] Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients [J].

Weisberg, E ;

Griffin, JD .

DRUG RESISTANCE UPDATES, 2001, 4 (01) :22-28

← 1 →